correction: nods for atezolizumab and nivolumab from fdatitle: correction: nods for atezolizumab and...
TRANSCRIPT
918 | CANCER DISCOVERY August 2017 www.aacrjournals.org
Correction: Nods for Atezolizumab and Nivolumab from FDA
CorreCtion
In this article (Cancer Discov 2016;6:811), which was published in the August 2016 issue of Cancer Discovery (1), the Ventana PD-L1 (SP142) assay, a complementary diagnostic, was incor-rectly referred to as a companion diagnostic. The online version of the article has been corrected. The publisher regrets the error.
doi: 10.1158/2159-8290.CD-17-0566©2017 American Association for Cancer Research.
Published OnlineFirst July 7, 2017.
ReFeReNCe1. Nods for atezolizumab and nivolumab from FDA. Cancer Discov 2016;6:811.
18-CD-17-0566_p918.indd 918 7/20/17 9:46 AM
Cancer Research. on February 16, 2021. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from
Published OnlineFirst July 7, 2017; DOI: 10.1158/2159-8290.CD-17-0566
2017;7:918. Published OnlineFirst July 7, 2017.Cancer Discov Correction: Nods for Atezolizumab and Nivolumab from FDA
Updated version
10.1158/2159-8290.CD-17-0566doi:
Access the most recent version of this article at:
Cited articles
http://cancerdiscovery.aacrjournals.org/content/7/8/918.full#ref-list-1
This article cites 1 articles, 1 of which you can access for free at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
SubscriptionsReprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. (CCC)Click on "Request Permissions" which will take you to the Copyright Clearance Center's
.http://cancerdiscovery.aacrjournals.org/content/7/8/918To request permission to re-use all or part of this article, use this link
Cancer Research. on February 16, 2021. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from
Published OnlineFirst July 7, 2017; DOI: 10.1158/2159-8290.CD-17-0566